GlassScriptPhysician profile
Michelle Swan
NPI 1801578646
$2,890.96
in general payments reported to CMS, 2019-2025
20 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $527 · 2024: $1,053 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $663.08 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $446.93 | 2023-2025 | |
| Axsome Therapeutics, INC. | $298.64 | 2023-2025 | Auvelity |
| Lundbeck LLC | $217.14 | 2024-2025 | Rexulti |
| Corium, LLC | $180.11 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $157.93 | 2023-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $150.02 | 2024-2025 | Rexulti |
| Harmony Biosciences LLC | $126.50 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $91.33 | 2023-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $84.13 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $76.30 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.91 | 2024-2025 | Caplyta |
| Tris Pharma INC | $60.64 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $57.87 | 2025 | |
| Gilead Sciences, INC. | $56.28 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $49.73 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $34.92 | 2024-2025 | Trintellix |
| Almatica Pharma LLC | $32.65 | 2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $19.45 | 2024 | Austedo Xr |
| Mdd US Operations, LLC | $18.40 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Swan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.